Cytomed Therapeutics Limited Stock Performance

GDTC Stock   1.00  0.05  5.26%   
The firm shows a Beta (market volatility) of 0.22, which signifies not very significant fluctuations relative to the market. As returns on the market increase, CytoMed Therapeutics' returns are expected to increase less than the market. However, during the bear market, the loss of holding CytoMed Therapeutics is expected to be smaller as well. At this point, CytoMed Therapeutics has a negative expected return of -1.26%. Please make sure to confirm CytoMed Therapeutics' day median price, price action indicator, as well as the relationship between the accumulation distribution and potential upside , to decide if CytoMed Therapeutics performance from the past will be repeated at some point in the near future.

Risk-Adjusted Performance

Weakest

 
Weak
 
Strong
Over the last 90 days CytoMed Therapeutics Limited has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of unfluctuating performance in the last few months, the Stock's basic indicators remain rather sound which may send shares a bit higher in February 2026. The latest tumult may also be a sign of longer-term up-swing for the firm shareholders. ...more
1
CytoMed Therapeutics Secures Non-Dilutive Investment for Subsidiary LongevityBank from ICH Capital and Updates on New China Strategy
11/06/2025
2
Is CytoMed Therapeutics Limited stock attractive for income investors - July 2025 Reactions Technical Pattern Alert System - newser.com
11/12/2025
3
CytoMed Therapeutics Completes Acquisition of T Cell Technology from UK to Treat Cancers in China and India
11/18/2025
4
Why CytoMed Therapeutics Limited stock appears on watchlists - 2025 Price Momentum Reliable Trade Execution Plans - Newser
12/04/2025
5
MACD Signals Flash Warning for Aditya Birla Sun Life AMC Ltd Stock - Financial Sector Performance Watch These Before They Go Viral - bollywoodhelpline.com
12/29/2025
6
How buybacks impact CytoMed Therapeutics Limited stock value - Exit Point Risk Controlled Daily Plans - ulpravda.ru
01/08/2026
7
CytoMed Therapeutics New Year Update and seeks shareholders feedback on proposal to improve shareholder value for their patient capital - marketscreener.com
01/14/2026
Begin Period Cash Flow4.7 M
Total Cashflows From Investing Activities494.6 K

CytoMed Therapeutics Relative Risk vs. Return Landscape

If you would invest  239.00  in CytoMed Therapeutics Limited on October 28, 2025 and sell it today you would lose (139.00) from holding CytoMed Therapeutics Limited or give up 58.16% of portfolio value over 90 days. CytoMed Therapeutics Limited is currently does not generate positive expected returns and assumes 5.492% risk (volatility on return distribution) over the 90 days horizon. In different words, 49% of stocks are less volatile than CytoMed, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon.
  Expected Return   
       Risk  
Given the investment horizon of 90 days CytoMed Therapeutics is expected to under-perform the market. In addition to that, the company is 7.45 times more volatile than its market benchmark. It trades about -0.23 of its total potential returns per unit of risk. The Dow Jones Industrial is currently generating roughly 0.07 per unit of volatility.

CytoMed Therapeutics Target Price Odds to finish over Current Price

The tendency of CytoMed Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
Current PriceHorizonTarget PriceOdds to move above the current price in 90 days
 1.00 90 days 1.00 
over 95.3
Based on a normal probability distribution, the odds of CytoMed Therapeutics to move above the current price in 90 days from now is over 95.3 (This CytoMed Therapeutics Limited probability density function shows the probability of CytoMed Stock to fall within a particular range of prices over 90 days) .
Given the investment horizon of 90 days CytoMed Therapeutics has a beta of 0.22. This usually indicates as returns on the market go up, CytoMed Therapeutics average returns are expected to increase less than the benchmark. However, during the bear market, the loss on holding CytoMed Therapeutics Limited will be expected to be much smaller as well. Additionally CytoMed Therapeutics Limited has a negative alpha, implying that the risk taken by holding this instrument is not justified. The company is significantly underperforming the Dow Jones Industrial.
   CytoMed Therapeutics Price Density   
       Price  

Predictive Modules for CytoMed Therapeutics

There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as CytoMed Therapeutics. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of CytoMed Therapeutics' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Hype
Prediction
LowEstimatedHigh
0.051.006.45
Details
Intrinsic
Valuation
LowRealHigh
0.050.966.41
Details
Naive
Forecast
LowNextHigh
0.020.886.33
Details
1 Analysts
Consensus
LowTargetHigh
4.555.005.55
Details

CytoMed Therapeutics Risk Indicators

For the most part, the last 10-20 years have been a very volatile time for the stock market. CytoMed Therapeutics is not an exception. The market had few large corrections towards the CytoMed Therapeutics' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold CytoMed Therapeutics Limited, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of CytoMed Therapeutics within the framework of very fundamental risk indicators.
α
Alpha over Dow Jones
-1.36
β
Beta against Dow Jones0.22
σ
Overall volatility
0.43
Ir
Information ratio -0.26

CytoMed Therapeutics Alerts and Suggestions

In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of CytoMed Therapeutics for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for CytoMed Therapeutics can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.
CytoMed Therapeutics generated a negative expected return over the last 90 days
CytoMed Therapeutics has high historical volatility and very poor performance
CytoMed Therapeutics has some characteristics of a very speculative penny stock
The company reported the previous year's revenue of 52.01 K. Net Loss for the year was (1.84 M) with profit before overhead, payroll, taxes, and interest of 675.25 K.
CytoMed Therapeutics generates negative cash flow from operations
About 67.0% of the company shares are held by company insiders

CytoMed Therapeutics Price Density Drivers

Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of CytoMed Stock often depends not only on the future outlook of the current and potential CytoMed Therapeutics' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. CytoMed Therapeutics' indicators that are reflective of the short sentiment are summarized in the table below.
Common Stock Shares Outstanding11.5 M
Cash And Short Term Investments3.6 M

CytoMed Therapeutics Fundamentals Growth

CytoMed Stock prices reflect investors' perceptions of the future prospects and financial health of CytoMed Therapeutics, and CytoMed Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on CytoMed Stock performance.

About CytoMed Therapeutics Performance

By analyzing CytoMed Therapeutics' fundamental ratios, stakeholders can gain valuable insights into CytoMed Therapeutics' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if CytoMed Therapeutics has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if CytoMed Therapeutics has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
Last ReportedProjected for Next Year
Days Of Inventory On Hand8.9 K8.4 K
Return On Tangible Assets(0.23)(0.24)
Return On Capital Employed(0.34)(0.36)
Return On Assets(0.23)(0.24)
Return On Equity(0.26)(0.27)

Things to note about CytoMed Therapeutics performance evaluation

Checking the ongoing alerts about CytoMed Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for CytoMed Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
CytoMed Therapeutics generated a negative expected return over the last 90 days
CytoMed Therapeutics has high historical volatility and very poor performance
CytoMed Therapeutics has some characteristics of a very speculative penny stock
The company reported the previous year's revenue of 52.01 K. Net Loss for the year was (1.84 M) with profit before overhead, payroll, taxes, and interest of 675.25 K.
CytoMed Therapeutics generates negative cash flow from operations
About 67.0% of the company shares are held by company insiders
Evaluating CytoMed Therapeutics' performance can involve analyzing a variety of financial metrics and factors. Some of the key considerations to evaluate CytoMed Therapeutics' stock performance include:
  • Analyzing CytoMed Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
  • Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether CytoMed Therapeutics' stock is overvalued or undervalued compared to its peers.
  • Examining CytoMed Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
  • Evaluating CytoMed Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of CytoMed Therapeutics' management team can help you assess the Company's leadership.
  • Pay attention to analyst opinions and ratings of CytoMed Therapeutics' stock. These opinions can provide insight into CytoMed Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
It's essential to remember that evaluating CytoMed Therapeutics' stock performance is not an exact science, and many factors can impact CytoMed Therapeutics' stock market price. Therefore, it's also important to diversify your portfolio and not rely solely on one company or stock for your investments.

Complementary Tools for CytoMed Stock analysis

When running CytoMed Therapeutics' price analysis, check to measure CytoMed Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy CytoMed Therapeutics is operating at the current time. Most of CytoMed Therapeutics' value examination focuses on studying past and present price action to predict the probability of CytoMed Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move CytoMed Therapeutics' price. Additionally, you may evaluate how the addition of CytoMed Therapeutics to your portfolios can decrease your overall portfolio volatility.
Idea Breakdown
Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes
Efficient Frontier
Plot and analyze your portfolio and positions against risk-return landscape of the market.
Earnings Calls
Check upcoming earnings announcements updated hourly across public exchanges
Pattern Recognition
Use different Pattern Recognition models to time the market across multiple global exchanges
Premium Stories
Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
Sectors
List of equity sectors categorizing publicly traded companies based on their primary business activities
Portfolio Suggestion
Get suggestions outside of your existing asset allocation including your own model portfolios
Aroon Oscillator
Analyze current equity momentum using Aroon Oscillator and other momentum ratios
Stock Tickers
Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites